摘要目的:探究尤瑞克林联合重组组织型纤溶酶原激活剂（rt-PA）静脉溶栓对超出溶栓时间窗急性脑梗死患者神经功能缺损程度（NIHSS）评分及生活质量的影响。方法:选取2015年9月至2018年8月本院超出溶栓时间窗急性脑梗死患者86例，按治疗方案不同分组，各43例。对照组予以常规治疗，观察组予以尤瑞克林联合rt-PA静脉溶栓。统计对比两组不良反应发生率、治疗前、治疗后1 d、7 d、21 d NIHSS评分及治疗前、治疗后6个月生活质量（GQOLI-74）量表评分。结果:治疗前，两组患者NIHSS评分比较，差异无统计学意义（ P>0.05）；治疗后1 d、7 d、21 d，观察组NIHSS评分分别为（10.56±2.98）分、（6.30±2.58）分、（4.95±1.76）分，均低于对照组，差异均有统计学意义（均 P<0.05）；观察组不良反应发生率16.28%与对照组11.63%比较，差异无统计学意义（ P>0.05）；治疗后6个月，观察组躯体功能、心理功能、社会功能、物质生活状态评分分别为（68.69±6.87）分、（70.36±7.63）分、（70.26±7.81）分、（71.13±7.58）分，均高于对照组，差异均有统计学意义（均 P<0.05）。 结论:对超出溶栓时间窗急性脑梗死患者联合采用尤瑞克林、rt-PA静脉溶栓治疗，可促进患者神经功能缺损恢复，改善生活质量，且不会增加不良反应发生率，值得临床推广与应用。

abstractsObjective:To investigate the effect of intravenous thrombolysis with Ureklin and recombinant tissue plasminogen activator (rt-PA) on the degree of neurological deficit (NIHSS) and quality of life in patients with acute cerebral infarction beyond thrombolysis time window.Methods:86 patients with acute cerebral infarction who exceeded the time of thrombolysis were enrolled in our hospital from September, 2015 to August, 2018. They were divided into a control group and an observation group according the treatment schemes, with 43 cases in each group. The control group received routine treatment, and the observation group was treated by intravenous thrombolysis with Ureklin and rt-PA. The incidences of adverse reactions, the NIHSS scores before and 1, 7, and 21 days after the treatment, and the quality of life (GQOLI-74) scale before and 6 months after the treatment were statistically compared.Results:There was no statistical difference in the NIHSS score between these two groups before the treatment ( P>0.05). 1, 7, and 21 days after the treatment, the NIHSS scores of the observation group were (10.56±2.98), (6.30±2.58), and (4.95±1.76), which were lower than those of the control group (all P<0.05). The incidence of adverse reactions was 16.28% in the observation group, and was 11.63% in the control group ( P>0.05). 6 months after the treatment, the scores of body, psychological, social, and material functions were (68.69±6.87), (70.36±7.63), (70.26±7.81), and (71.13±7.58) in the observation group, which were higher those in the control group (all P<0.05). Conclusion:Intravenous thrombolysis with Ureklin and rt-PA for patients with acute cerebral infarction beyond the time of thrombolysis can promote the recovery of neurological deficits and improve their quality of life without increasing the incidence of adverse reactions. It is worthy of clinical promotion and application